Gilead circles February 12 on its calendar as D-day for its HIV franchise
It won’t be long now before Gilead gets an official answer on its marketing application for a new HIV triple with megablockbuster potential.
The FDA has put this application on the priority review track for its combination of bictegravir with its backbone HIV drugs emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF) — Gilead had filed this application with a priority review voucher — after the treatment posted impressive efficacy results.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.